These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 20811727)
1. In vitro novel combinations of psychotropics and anti-cancer modalities in U87 human glioblastoma cells. Tzadok S; Beery E; Israeli M; Uziel O; Lahav M; Fenig E; Gil-Ad I; Weizman A; Nordenberg J Int J Oncol; 2010 Oct; 37(4):1043-51. PubMed ID: 20811727 [TBL] [Abstract][Full Text] [Related]
2. Synergistic interactions between camptothecin and EGFR or RAC1 inhibitors and between imatinib and Notch signaling or RAC1 inhibitors in glioblastoma cell lines. Sooman L; Ekman S; Andersson C; Kultima HG; Isaksson A; Johansson F; Bergqvist M; Blomquist E; Lennartsson J; Gullbo J Cancer Chemother Pharmacol; 2013 Aug; 72(2):329-40. PubMed ID: 23736154 [TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of primary glioblastoma cell lines from fresh and frozen material: a detailed comparison. Mullins CS; Schneider B; Stockhammer F; Krohn M; Classen CF; Linnebacher M PLoS One; 2013; 8(8):e71070. PubMed ID: 23951083 [TBL] [Abstract][Full Text] [Related]
4. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells. Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279 [TBL] [Abstract][Full Text] [Related]
5. Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway. Fu J; Zhu SH; Xu HB; Xu YQ; Wang X; Wang J; Kong PS J Ethnopharmacol; 2020 Oct; 261():113071. PubMed ID: 32603676 [TBL] [Abstract][Full Text] [Related]
6. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide. Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059 [TBL] [Abstract][Full Text] [Related]
7. The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures. Narayan RS; Fedrigo CA; Brands E; Dik R; Stalpers LJ; Baumert BG; Slotman BJ; Westerman BA; Peters GJ; Sminia P BMC Cancer; 2017 Mar; 17(1):204. PubMed ID: 28320338 [TBL] [Abstract][Full Text] [Related]
8. Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells. Failly M; Korur S; Egler V; Boulay JL; Lino MM; Imber R; Merlo A Mol Cancer Ther; 2007 Feb; 6(2):773-81. PubMed ID: 17308073 [TBL] [Abstract][Full Text] [Related]
9. In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. Ranza E; Mazzini G; Facoetti A; Nano R J Neurooncol; 2010 Feb; 96(3):349-57. PubMed ID: 19629393 [TBL] [Abstract][Full Text] [Related]
10. Temozolomide treatment combined with AZD3463 shows synergistic effect in glioblastoma cells. Goker Bagca B; Ozates NP; Asik A; Caglar HO; Gunduz C; Biray Avci C Biochem Biophys Res Commun; 2020 Dec; 533(4):1497-1504. PubMed ID: 33109342 [TBL] [Abstract][Full Text] [Related]
11. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells. Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856 [TBL] [Abstract][Full Text] [Related]
12. Carvedilol in glioma treatment alone and with imatinib in vitro. Erguven M; Yazihan N; Aktas E; Sabanci A; Li CJ; Oktem G; Bilir A Int J Oncol; 2010 Apr; 36(4):857-66. PubMed ID: 20198329 [TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells. Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709 [TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Martins AS; Mackintosh C; Martín DH; Campos M; Hernández T; Ordóñez JL; de Alava E Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3532-40. PubMed ID: 16740780 [TBL] [Abstract][Full Text] [Related]
15. Melanocortin Receptor-4 and Glioblastoma Cells: Effects of the Selective Antagonist ML00253764 Alone and in Combination with Temozolomide In Vitro and In Vivo. Vaglini F; Pardini C; Di Desidero T; Orlandi P; Pasqualetti F; Ottani A; Pacini S; Giuliani D; Guarini S; Bocci G Mol Neurobiol; 2018 Jun; 55(6):4984-4997. PubMed ID: 28791594 [TBL] [Abstract][Full Text] [Related]
16. High-Dose Metformin Plus Temozolomide Shows Increased Anti-tumor Effects in Glioblastoma In Vitro and In Vivo Compared with Monotherapy. Lee JE; Lim JH; Hong YK; Yang SH Cancer Res Treat; 2018 Oct; 50(4):1331-1342. PubMed ID: 29334602 [TBL] [Abstract][Full Text] [Related]
17. Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells. Castro-Gamero AM; Borges KS; Moreno DA; Suazo VK; Fujinami MM; de Paula Gomes Queiroz R; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG Invest New Drugs; 2013 Aug; 31(4):858-70. PubMed ID: 23299390 [TBL] [Abstract][Full Text] [Related]
18. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3-mediated mitochondrial and PI3K/Akt-MAPK pathway. Wang G; Fu XL; Wang JJ; Guan R; Sun Y; Tony To SS J Cell Physiol; 2019 May; 234(5):5888-5903. PubMed ID: 29336479 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]